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Natural killer (NK) cells, which recognize and kill target cells independent of antigen specificity and major histocompatibility 
complex (MHC) matching, play pivotal roles in immune defence against tumors. However, tumor cells often acquire the ability 
to escape NK cell-mediated immune surveillance. Thus, understanding mechanisms underlying regulation of NK cell pheno-
type and function within the tumor environment is instrumental for designing new approaches to improve the current 
cell-based immunotherapy. In this review, we elaborate the main biological features and molecular mechanisms of NK cells 
that pertain to regulation of NK cell-mediated anti-tumor activity. We further overview current clinical approaches regarding 
NK cell-based cancer therapy, including cytokine infusion, adoptive transfer of autologous or allogeneic NK cells, applications 
of chimeric antigen receptor (CAR)-expressing NK cells and adoptive transfer of memory-like NK cells. With these promising 
clinical outcomes and fuller understanding the basic questions raised in this review, we foresee that NK cell-based approaches 
may hold great potential for future cancer immunotherapy. 
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Cancer is a major public health problem all over the world. 
In China, it is currently the second leading cause of death 
after heart disease, and is expected to be the foremost cause 
of death in the next few years. Traditional treatments for 
cancer include surgery, chemotherapy, and radiation therapy 
depending on the location of the tumor, the malignant  
degrees of carcinoma, and the stages of cancer develop- 
ment [1,2]. However, the arising resistance to drugs or radi-
ation leads to a significant ratio of tumor recurrence. 
Therefore, it is crucial to develop new therapeutic strategies 
to eradicate drug-resistant tumor cells. Cancer immuno-
therapy that aims to elicit or amplify the patient’s own im-
mune response to eliminate tumor cells has recently 
emerged as one of such promising approaches.  
The host immune response is composed of two intercon-
nected arms: innate immunity and adaptive immunity. The 
innate immune system, also known as the nonspecific im-
mune system, utilizes the germline-encoded molecular and 
cellular mechanisms to provide the first line of defense 
through immediate responses to foreign antigens. In con-
trast, the adaptive immune system, also known as the ac-
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quired immune system, is composed of highly specialized 
cellular subsets that recognize and eliminate the foreign 
invaders via their antigen-specific receptors, and generates 
immunological memory after an initial encounter to a spe-
cific pathogen, leading to a more intensive response to the 
same pathogen. NK cells have traditionally been recognized 
as innate lymphoid cells due to their rapid response to target 
cells without prior sensitization. Unlike T cells, NK cells 
are always switched on and can recognize target cells inde-
pendent of antigen specificity and MHC matching, which 
allows anti-tumor effects without eliciting strong graft- 
versus-host disease (GvHD) responses. Moreover, NK cell 
based therapy will potentially be cheaper, more scalable and 
have a lower latency period from treatment decision to re-
ceipt of therapy compared to T-cell based competitors [3,4]. 
Therefore, approaches that utilize NK cells for cancer im-
munotherapy are gaining more and more attention world- 
wide. For example, in China, researchers attempt to sup-
press the recurrence of Hepatocellular carcinoma (HCC) 
after liver transplantation using NK Cells from sibship 
(ClinicalTrials.gov. NCT02399735); in France, scientists 
have initiated a trial to infuse haploidentical NK cells into 
patients bearing acute myeloid leukemia (AML) 
(NCT01947322); in Germany, NK cell-based adoptive im-
munotherapy is currently used for the treatment of patients 
with non-small cell lung cancer (NSCLC) (NCT02118415); 
in the USA, infusion of cytokine-induced memory-like NK 
cells into patients with AML or myeloid dysplastic syn-
dromes (MDS) has already obtained a certain extent of suc-
cess (NCT01898793); and umbilical cord blood NK cell 
transfer has been introduced as part of the therapy for pa-
tients with chronic lymphocytic leukemia (CLL) 
(NCT02280525). More clinical studies are summarized in 
table 1.  
The present review summarizes the concepts and ra-
tionale for the clinical application of NK cells in cancer 
immunotherapy. We further overview strategies that can 
optimize NK cell cytotoxicity and alloreactivity for the im-
provement of therapeutic efficacy in the clinical practice. 
1  NK cell biology 
1.1  NK cell phenotype 
In the mid-1970s, NK cells were originally identified by 
Kiessling as a sub-population of lymphocytes in mice that 
are larger in size than T and B lymphocytes and have the 
capacity to kill tumor cells without prior sensitization [5–7]. 
Since then, major advances in the understanding of NK cell 
biology have provided significant insights into its role in 
controlling various tumors and infections [8]. It is widely 
known that conventional NK cells originate from common 
lymphoid progenitor cells and further differentiate into im-
mature/mature NK cells in bone marrow (BM) that are then 
distributed in peripheral lymphoid and non-lymphoid organs 
and tissues, including BM, lymph nodes (LN), spleen,  
peripheral blood, placenta, lung, liver and peritoneal  
cavity [9–12]. Resting NK cells that account for 10%–15% 
of peripheral blood lymphocytes circulate in the blood. Af-
ter responding to a large array of cytokines and chemokines, 
they are capable of extravasation and recruitment into dis-
tinct inflamed or malignant tissues [13]. Human mature NK 
cells can be subdivided into two distinct major sub-    
populations based on cluster of differentiation 56 (CD56) 
expression levels, i.e. low CD56-expressing (CD56dim) and 
high CD56-expressing population (CD56bright). CD56dim 
subsets predominately reside in peripheral blood 
(90%–95%) and inflammatory sites, which exhibit a high 
cytotoxic potential after encountering target cells [14–16]. 
In contrast, approximately 90% NK cells in secondary 
lymphoid tissues belong to the CD56bright population that 
primarily exerts immunoregulatory function by producing 
abundant cytokines or chemokines [16,17]. Although mu-
rine NK cells do not express the CD56 receptor, the devel-
opmental status, homing properties and functional attributes 
of murine NK cells can be represented by four subsets ac-
cording to the expression of CD11b and CD27: 
CD11bloCD27lo, CD11bloCD27hi, CD11bhiCD27hi, 
CD11bhiCD27lo [18]. Further studies on human NK subsets 
defined by CD11b and CD27 markers have also revealed 
four populations with distinct maturation stages, tissue dis-
tribution patterns and functional properties [19,20]. Moreo-
ver, these studies have showed that the CD56bright popula-
tion remains heterogenous. Thus, further understanding of 
distinct properties of these NK subsets at the steady state or 
under inflammatory/tumor settings may be instrumental for 
designing clinical applications of NK cells. 
1.2  NK cell-mediated recognition mechanisms 
A current consensus is that NK cell cytotoxicity is modu-
lated by an intricate balance between signals emanating 
from surface inhibitory receptors and those from activating 
receptors. NK cells are quiescent when encountering normal 
or healthy cells that express adequate MHC molecules for 
NK inhibitory receptors and no or few activating ligands. 
NK cell cytotoxicity is otherwise triggered when target 
“dangerous” cells exhibiting a reduced or altered MHC out-
fit along with the enough activating ligands expression [21]. 
Three recognition models have currently been proposed: 
“missing-self recognition”, “stress induced-self recognition” 
and “non-self recognition”. Under stressed conditions, such 
as cellular transformation, down-regulated MHC molecules 
expression by normal cells, resulting in NK cell activation 
in a process called “missing-self recognition”. This model is 
based on the fact that NK cell activity is normally held in 
check by self-MHC molecules that interact with a large 
repertoire of inhibitory NK receptors, including the hetero- 
dimeric C-type lectin-like receptor (CTLR) called 
CD94/NKG2A (natural killer group protein 2 family mem-
ber A) [22], the NK-gene complex (NKC)-encoded CTLR  
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Table 1  Clinical trials of NK cells in cancer immunotherapy 
NCT Number Age Groups Patients Phases Conditions 
NCT01944982 Child|Adult 10 Phase 1 |Phase 2 Relapsed/Refractory Pediatric T Cell Lymphoblastic Leukaemia and Lym-
phoma 
NCT01795378 Child|Adult|Senior 85 Phase 1 |Phase 2 Acute Myelogenous Leukemia|Acute Lymphoblastic Leukemia 
NCT02130869 Child|Adult 36 Phase 1 Neuroblastoma|Lymphoma|High-risk Tumor 
NCT02280525 Adult|Senior 44 Phase 1 Leukemia 
NCT01787474 Adult 30 Phase 1 |Phase 2 Leukemia 
NCT01823198 Child|Adult 72 Phase 1 |Phase 2 Leukemia 
NCT02271711 Child|Adult 24 Phase 1 Brain Cancer 
NCT02074657 Child|Adult 10 Phase 2 Relapsed/Refractory Pediatric Acute Leukemia 
NCT01884688 Adult|Senior 20 Phase 2 Asymptomatic Multiple Myeloma 
NCT02316964 Adult|Senior 10  Adult Acute Myeloid Leukemia with 11q23 (MLL) abnormalities|Adult  
Acute Myeloid Leukemia with Del(5q)|Adult Acute Myeloid Leukemia  
with Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia with  
t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia with  
t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia with  
t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia|Secondary  
Acute Myeloid Leukemia 
NCT02100891 Child|Adult|Senior 20 Phase 2 Ewing Sarcoma|Neuroblastoma|Rhabdomyosarcoma 
NCT01904136 Child|Adult 45 Phase 1 |Phase 2 Leukemia|Myeloproliferative Diseases 
NCT02291198 Adult|Senior 1000  Natural Killer Cell Cytokine Production 
NCT01974479 Child|Adult|Senior 20 Phase 2 B-cell Acute Lymphoblastic Leukemia 
NCT02118285 Adult|Senior 20 Phase 1 Ovarian Cancer|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma 
NCT02259348 Child|Adult 18 Phase 2 Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia  
(AML)|Myeloid Sarcoma|Chronic Myelogenous Leukemia (CML)|Juvenile 
Myelomonocytic Leukemia (JMML)|Myelodysplastic Syndrome  
(MDS)|Non-Hodgkin Lymphoma (NHL) 
NCT02019628 Adult|Senior 20  Family Member 
NCT02118415 Adult|Senior 90 Phase 2 NSCLC Stage IIIA/B 
NCT02185781 Adult|Senior 6 Phase 1 Acute Lymphoblastic Leukemia|Complete Hematologic Remission  
(CHR)|Persistent/Recurrent Minimal Residual Disease (MRD) 
NCT02409576 Child|Adult|Senior 20 Phase 1 |Phase 2 Ewing Sarcoma|Osteosarcoma|Rhabdomyosarcoma 
NCT01857934 Child|Adult 42 Phase 2 Neuroblastoma 
NCT02326727 Adult|Senior 30  Colonic Neoplasms 
NCT02229266 Adult|Senior 56 Phase 2 Acute Myeloid Leukemia 
NCT02477787 Adult|Senior 96 Phase 2 Acute Myelogenous Leukemia 
NCT02123836 Child|Adult|Senior 20 Phase 1 Acute Leukemia|Myelodysplastic Syndrome 
NCT01790269 Adult 40  Relapsing-Remitting Multiple Sclerosis 
NCT01807611 Child|Adult 110 Phase 2 Leukemia|Lymphoma 
NCT02395822 Adult|Senior 24 Phase 2 Acute Myelogenous Leukemia 
NCT02399735 Adult 18 Phase 1 Hepatocellular Carcinoma 
NCT01947322 Adult 11 Phase 1 |Phase 2 Acute Myeloid Leukemia 
NCT02465957 Adult|Senior 24 Phase 2 Stage IIIB Merkel Cell Carcinoma|Stage IV Merkel Cell Carcinoma 
NCT02370017 Adult|Senior 68 Phase 2 Non-small Cell Lung Cancer 
NCT02301065 Child|Adult 100  Hematologic Malignancies 
NCT01875601 Child|Adult 51 Phase 1 Solid Tumors|Brain Tumors|Sarcoma|Pediatric Cancers|Neuroblastoma 
NCT02030561 Adult|Senior 29 Phase 1 |Phase 2 Breast Cancer|Gastric Cancer 
NCT01898793 Adult|Senior 24 Phase 1 Leukemia, Myeloid, Acute 
NCT01807468 Child|Adult 12 Phase 2 Neuroblastoma|Ewing Sarcoma|Rhabdomyosarcoma|Osteosarcoma|Soft 
Tissue Sarcoma 
NCT02481934 Adult|Senior 5 Phase 1 Multiple Myeloma 
NCT01853358 Adult|Senior 22 Phase 1 Hematological Malignancy 
NCT01841294 Adult|Senior 50 Phase 4 Colorectal Cancer 
 
named KLRG1 (killer cell lectin-like receptor subfamily G, 
member 1) [23] and members of killer-immunoglobulin like 
(KIR) family [24]. The numbers and subtypes of the KIR 
receptors are different in each individual [25]. The inhibi-
tory KIRs that recognize human leukocyte antigen (HLA) 
class I proteins (HLA-A, -B, and -C) contain immunore-
ceptor tyrosine-based inhibitory motifs (ITIMs), which can 
recruit and activate SH2-containing protein tyrosine phos-
phatase (SHP)-1 and SHP-2, leading to inhibition of NK 
cells. Another ITIM-containing inhibitory receptor—human 
CD94/NKG2A heterodimers—binds to HLA-E, a 
non-classical HLA class I molecule, which also induces 
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inhibition of NK cells [26]. In addition, KLRG1 recognizes 
cadherin, which is often downregulated on epithelial tumor 
cells during tumor progression [27]. 
“Stress induced-self recognition” refers to that a number 
of NK activating receptors recognize self-proteins, which 
are upregulated in transformed or infected cells. The natural 
killer group protein 2 Family member D (NKG2D) activat-
ing receptor is constitutively expressed in all NK cells and 
recognizes UL16-binding proteins and the major histocom-
patibility complex class I chain-related genes A/B 
(MICA/MICB) in humans. Ligation of NKG2D and its lig-
ands induces phosphorylation of the adapter protein 
DNAX-activating protein of 10 kD (DAP10), which con-
tains a cytoplasmic tyrosine-isoleucine-asparagine-  me-
thionine (YINM) motif that upon phosphorylation leads to 
recruitment and activation of the p85 subunit of phosphati-
dylinositol-3-kinase (PI-3K), and subsequently induces NK 
cell activation [28,29]. Several members of activating KIR 
or NKG2 family, such as killer cell immunoglobulin-like 
receptor, two domains, short cytoplasmic tail (KIR2DS), 
killer cell immunoglobulin-like receptor, three domains, 
short cytoplasmic tail (KIR3DS), natural killer group pro-
tein 2 family member C (NKG2C) and natural killer group 
protein 2 family member E (NKG2E), contain the immuno-
receptor tyrosine-based activation (ITAM)-bearing adaptor 
DAP12 that also exhibits immunostimulatory activity once 
the receptors are triggered [24,30,31]. In addition, 
DNAM-1, NKp80 and 2B4 (CD244) bind to ligands ex-
pressed by both normal and malignant cells, which induces 
NK cell activation under both circumstances [32–35]. 
“Non-self recognition” indicates that some NK activating 
receptors do not recognize endogenous ligands but interact 
with foreign pathogen-encoded molecules. For example, 
NKp46 and NKp44 recognize hemagglutinins derived from 
influenza and sendai viruses; NKp30 recognizes pp65 teg-
ument protein from human cytomegalovirus and 2B4 rec-
ognizes Epstein-Barr virus-infected B cells [35–38]. These 
pairs of receptor-ligand interaction ultimately lead to NK 
cell activation. 
1.3  NK cell function in innate and adaptive immunity 
NK cells are initially regarded as cytotoxic lymphocytes 
that contribute to immune defense against infections and 
tumor transformation (Figure 1). NK cells are able to lyse 
target cells without prior sensitization through three major 
pathways: (i) Direct cytotoxicity by release of granules 
containing perforins and granzymes that induce apoptosis of 
target cells [39,40]. (ii) Lysis of targets through apoptotic 
pathways induced by ligation of tumor-necrosis factor 
(TNF) family members expressed by NK cells, such as FasL 
or TNF-related apoptosis-inducing ligand (TRAIL) [41–43].  
 
 
Figure 1 (color online)  Functional activities of natural killer cells. The diagram presents the known and predicted roles of human NK cells in immune 
surveillance and regulation. NK cells can directly eliminate target cells to resolve infection and induce tumor regression. NK cells are also known to function 
as regulatory cells by inducing the activation, maturation or demise of other immune subsets, such as activated CD4+ T cells, hyperactivated macrophages 
and DCs, which enables NK cells with the capacity to regulate immune homeostasis and autoimmune/inflammatory responses. In addition, NK cells may 
also regulate processes in reproduction and transplantation. 
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(iii) Lysis of targets through antibody-dependent cellular 
cytotoxicity (ADCC) by triggering the NK CD16 receptor,  
which binds to the IgG and antibody-coated targets [44]. 
NK cells are also known to function as regulatory cells  
that act as a link between the adaptive and innate immune 
responses and control immune homeostasis, inflammatory 
and autoimmune responses (Figure 1). They modulate other 
immune subsets by direct contact or releasing various cyto-
kines/chemokines. NK cells have been demonstrated as the 
major source of IFN- in vivo, which is considered to be 
crucial in restricting tumor angiogenesis and shaping adap-
tive immunity [45–47]. IFN- from NK cells after stimula-
tion with exogenous cytokines or through target cell recog-
nition promotes the differentiation of CD4+ T helper 1 sub-
set (TH1) and helps priming CD8
+ cytotoxic T-cell (CTL) 
response. However, NK cells can also exert negative regu-
latory effects on TH cells, including TH17 and follicular 
helper T cells (TFH), in the context of autoimmunity [48,49]. 
Some NK subsets suppress T-cell responses by producing 
regulatory cytokines, including IL-5, IL-13, IL-10 or trans-
forming growth factor Beta (TGF-. NK cells also cross-
talk with dendritic cells (DC) and macrophages and influ-
ence the overall immune responses [50,51]. For example, 
NK cells facilitate DC maturation and cytokine production, 
which further regulates antigen-specific T-cell responses; 
NK cells interact with macrophages and amplify the in-
flammatory response [50]. Epidemiologic reports and cellu-
lar analysis also indicate that NK cells may regulate other 
biological processes, including those in reproduction and 
transplantation (Figure 1). Future studies are required to 
better understand these NK cell-mediated regulatory activi-
ties.  
Traditionally, NK cells are considered as innate lym-
phoid cells since they lack the ability to undergo somatic 
rearrangements that induce the expression of antigen-  
specific receptors. However, several recent studies demon-
strate that NK cells display adaptive or “memory-like” 
properties both in human and mice, including long-term 
persistence, enhanced functional responsiveness and other 
phenomena that phenotypically and epigenetically distinct 
from their naive counterparts after pathogen infection  
or exposure to other stimulation. Human studies have 
demonstrated that infections with cytomegalovirus  
(CMV) [52–54], hantavirus [55], or chikungunya virus [56] 
result in an increased number of NKG2C+ NK cells. Func-
tionally, these NKG2C+ NK cells produce more IFN- in 
response to target cells than their naive counterparts [52]. 
Furthermore, adoptively transferred NKG2C+ NK cells from 
CMV-seropositive persons in recipients display enhanced 
effector function against a secondary CMV challenge com-
pared to those in recipients who receive NKG2C+ NK cells 
from CMV-seronegative individuals, suggesting that a prior 
sensitization of NKG2C+ NK cells is necessary for the gen-
eration of memory-like responses [57]. 
1.4  Cross-talk between NK cells and other immune 
cells in cancer 
The tumor initiation and progression are associated with 
aberrant regulation of multiple immune subsets, including 
T-cells, DCs and NK cells, under tumor-induced immuno-
suppressive conditions. A large population of tumor-   
infiltrating NK cells displays the immature CD11bloCD27lo 
phenotype [20]. Some of these NK cells upregulate inhibi-
tory receptors, such as PD-1 and Tim-3, indicative of NK 
cell exhaustion [58]. The maturation arrest of NK cells and 
impaired NK cytotoxicity in patients bearing tumors are 
often attributed to the abnormal immune subsets that secrete 
various suppressive cytokines and/or enzymes. For exam-
ple, tumor-associated accumulation of regulatory T-cells 
can produce TGF- that downregulates the activating 
NKp30 and NKG2D receptors and impairs the tumouricidal 
activity of NK cells and the functional interactions between 
NK cells and DCs [59]. The bidirectional crosstalk between 
NK cells and DCs (as described in section 2.3) plays an 
important role in the induction of optimal CTL-mediated 
tumor-specific immune response against cancer, which has 
provided the rationale for the combined application of NK 
cells and DCs in the cancer immunotherapy. However, 
dysregulated NK cells in tumor microenviroment can also 
lead to accumulation of immature or tolerogenic DCs [60], 
which impairs anti-tumor CTL responses and aggravates the 
immunosuppression [59]. 
1.5  Epigenetic regulation of NK cells 
Epigenetic regulation refers to functionally relevant modi-
fications to the genome that impact gene expression, cellu-
lar phenotypic and functional traits without inducing 
changes in the nucleotide sequence. Such modifications 
include DNA methylation; and acetylation, methylation and 
phosphorylation of the N-terminal tails of histone proteins; 
as well as the reverse processes of these modifications, 
which can induce changes in chromatin configuration on 
target gene loci. Cells utilize these mechanisms to integrate 
genetic programs with external or environmental signals in 
order to establish or maintain cellular identity. Although 
epigenetic regulation of the differentiation and function of 
T- and B-cells is well-characterized, less is understood re-
garding its role in NK cell development and function. Vi-
jayalakshmi and his colleagues have recently observed that 
the histone H2A deubiquitinase Myb-Like, SWIRM and 
MPN domains 1 (MYSM1) is necessary for NK cell  
maturation but not for NK lineage specification and com-
mitment [61]. Most recently, our group has discovered that 
the histone methyltranferase Ezh2 enhances NK develop-
ment, in part through repression of NKG2D through the 
histone H3K27me3 modification on its regulatory locus 
(unpublished data). Many studies have also shown that epi-
genetic controls of genes encoding IFN, perforin and 
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granzymes are important for NK cell function [62].  
Conclusive evidence has indicated that changes in chro-
matin scaffold in the precursors can be passed on to daugh-
ter cells, forming the basis for memory. Although epigenetic 
regulation has been well illustrated in memory T-cells [63], 
less is understood with regards to mechanisms underlying 
the formation of “memory-like” NK cells. Two independent 
studies have recently revealed that memory-like NK subsets 
in HCMV (Besides Human cytomegalovirus)-infected indi-
viduals display reduced expression of many signaling pro-
teins and transcription factors, which are associated with 
hypermethylation of their gene promoters [64,65]. Further 
understanding of the epigenetic regulation of NK cell dif-
ferentiation, memory formation and functional specializa-
tion may require generation of conditional mouse models 
that induce NK cell-specific deletion of crucial epigenetic 
modifiers. Genome-wide chromatin immunoprecipitation 
sequencing coupled with transcriptional profiling studies 
may help reveal the regulatory network that determines NK 
cell fate and functionality. 
2  NK cell-based immunotherapy in malignancy 
During the tumor development and progression, many ma-
lignant cells acquire the ability either to evade from NK-cell 
recognition or to impair NK cell function. Several general 
mechanisms are suggested including inaccessibility of NK 
cells to the tumor due to defective vascularization, deficient 
expression of adhesion molecules or activating receptors on 
NK cells, high expression of MHC class I on tumor cells, 
resistance to the Fas- or perforin-mediated apoptosis and 
secretion of immunosuppressive factors such as IL-10 or 
TGF- by tumors [1,66]. Therefore, approaches to improve 
cytotoxicity or restore immune system are necessary to ef-
fectively enhance cancer immunotherapy. The success of 
chimeric antigen receptors (CARs) T cell therapy in cases 
of ALL and CLL has revitalized cell-based therapies as one 
of the promising approaches for the treatment of malignan-
cy. In contrast to T cells, NK cell-mediated cytotoxicity 
does not require the antigen presentation by self-HLA. 
Thus, cancer cells can be recognized by allogeneic NK cells 
based on ‘‘missing-self recognition” mechanism. Moreover, 
NK cells are known to contribute to graft-versus-tumor 
(GvT) effect but do not induce graft-versus-host disease 
(GvHD). Based on these unique properties of NK cells, the 
therapeutic use of autologous or allogeneic NK cells may 
provide a pivotal and clinical significance in human cancer 
immunotherapy (Figure 2). 
2.1  Cytokine-induced NK cell activation  
Tumorigenesis is a delicate process, which is under the 
stringent surveillance of NK cells as well as other immune  
 
 
Figure 2 (color online)  Schematic diagram for cancer immunotherapy by NK cells. The diagram shows an overview of current approaches to NK 
cell-based cancer immunotherapy. A, NK cell activity can be modulated in vivo by cytokine infusion. Autologous (B) or allogeneic (C) NK cells can be 
expanded or activated with cytokines in vitro prior to infusion into patients. D, NK cells can be genetically modified prior to infusion. E, Transfer of cyto-
kine-induced memory-like (CIML) NK cells can provoke robust and effective anti-tumor responses. 
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subsets. During tumor progression, many cancer cells obtain 
the ability to escape immunosurveillance. In the early days, 
the therapeutic methods were focused on either improving 
the antitumor activity of NK cells, or promoting NK cell 
expansion. It is well-known that IL-2, a growth factor that 
induces proliferation and expansion of lymphocytes and 
plays key roles in immune responses, can activate NK cells 
and enhance NK cytotoxicity against malignant cells [67]. 
Many studies using animal models have demonstrated the 
effectiveness of IL-2 on NK cell activation and anti-tumor 
responses [68–81]. Robinson and Morstyn [82] has also 
reported that NK cells from lung cancer patients that fail to 
kill tumor cells, can regain the cytotoxicity against targets 
after activation by IL-2. Although the FDA has approved 
the IL-2-based therapy for renal cell carcinoma (RCC) in 
1992, the clinical results are not satisfactory due to the lim-
ited anti-tumor activity of NK cells and excessive toxicity 
when high doses of cytokine are administered. Rosenberg et 
al. [83] has first reported that systemic administration of 
autologous lymphokine can activate killer cells and applica-
tion of recombinant IL-2 (rIL-2) induces remission in pa-
tients with advanced cancer. This promising outcome has 
revealed a cytokine-based strategy for cancer therapy that 
has drawn wide attention, albeit with some observed side 
effects. A phase I/II trial reported that daily subcutaneous 
injection of IL-2 supplemented with two intravenous injec-
tions can generate peripheral blood mononuclear cells 
(PBMCs) with enhanced cytotoxicity against NK-resistant 
targets, but showed limited efficacy when compared with 
matched controls [84]. A similar study that uses regional 
arterial administration of lymphokine-activated killer cells 
(LAK) and low doses of rIL-2 also did not lead to satisfied 
clinical success [85]. 
Overall, data from the previous reports have showed 
some promising outcomes. However, activation of NK cells 
using high-dose IL-2 in vivo has significant but manageable 
side effects because of severe capillary leaky syndrome. 
Moreover, recipient regulatory T cells, which express high 
affinity IL-2 receptor  chain (CD25) and are more sensi-
tive to low dose IL-2, can compete with CD56bright NK cells 
for cytokines and “space” and induce immune suppression. 
Thus, low-dose IL-2 treatment is not an optimum method 
for most candidates. Based on these studies, some groups 
combined IL-2 and other NK cell activators to improve the 
therapeutic efficacy and safety. Hellstrand et al. [86] ad-
ministered IL-2 together with histamine to 22 AML pa-
tients, and showed a good clinical outcome. In addition, 
21/22 complete remission (CR) patients could treat them-
selves with histamine at home throughout the trial. Other 
researchers combined IL-2 and IFN- to induce a signifi-
cant increase in peripheral blood NK cells [87–89]. Im-
proved expansion and/or activation of various effector cells, 
including NK cells, were also reported after combined use 
of IL-2, IFN- and GM-CSF [90]. In a different strategy 
from the above researchers, Bachanora et al. [91] utilized 
IL-2 diphtheria toxin (IL2DT), a recombinant cytotoxic 
fusion protein composed of the amino acid sequences of 
diphtheria toxin and truncated amino acid sequences of 
IL-2, to deplete Treg cells, and therefore improve donor NK 
cell expansion. In this study, they performed high-dose cy-
clophosphamide and fludarabine (Hi-Cy/Flu) lym-
phodepleting chemotherapy and adoptive transfer of al-
logeneic NK cells to treat refractory AML patients, and 
among these candidates, fifteen patients also received 
IL2DT. These patients exhibited improved complete remis-
sion rates at day 28 (53% vs 21%) and disease-free survival 
at 6 months (33% vs 5%). These data demonstrate that de-
pletion of host Tregs, which exhibit sensitivity to low dose 
IL-2, is associated with improved in vivo donor NK-cell 
expansion and remission induction. 
2.2  Adoptive transfer of autologous NK cells 
Based on a series of investigations with successful experi-
mental animal models, various researchers hold the view 
that adoptive transfer of autologous NK cells is safe and 
promising [81,92–94]. Ten metastatic RCC patients re-
ceived a combination of high-dose IL-2 and lympho-
kine-activated natural killer (LANAK) cell infusions. Par-
tially effective clinical outcomes were observed with four 
complete responses and two additional patients whose tu-
mor mass was further reduced [95]. Ishikawa et al. [96] in-
jected autologous NK cells together with IFN- into 9 pa-
tients with recurrent malignant glioma and showed that NK 
cell therapy was safe and partially effective. However, 
Burns et al. [84] treated non-Hodgkin’s lymphoma and 
RCC patients with ex vivo IL-2–activated autologous NK 
cells followed by daily subcutaneous IL-2 injection, which 
demonstrated no improvement in the disease status. Studies 
from other groups involved with metastatic breast cancer, 
colon cancer and lung cancer also failed to observe that 
transfer of autologous NK cells was consistently effective in 
patients [97–100]. After analyzing the clinical data men-
tioned above, Alici et al. [101] believed that failure to re-
cover the NK cytotoxicity was due to insufficient NK cell 
activation. They further compared the effectiveness of 
long-term with short-term activation of NK cells from mul-
tiple myeloma (MM) patients and found that long-term ac-
tivation can significantly enhance NK cytotoxicity against 
autologous tumor cells. However, Miller and his colleague 
conceived that many tumors expressing high levels of HLA 
class I receptor and/or low levels of ligands for activating 
receptors are largely resistant to the NK-cell-mediated lysis. 
Thus, they are currently focusing on therapies using allo-
genic NK cells or other strategies to prevent such NK cell 
resistance (described below).  
2.3  Adoptive transfer of allogeneic NK cells 
Previous clinical observations and basic science research 
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have greatly improved our understanding of functionality of 
NK cells within hosts bearing different MHC genotypes. 
Autologous NK cells are unable to kill host tumor cells due 
to inhibition by self-MHC or by tumor-induced immuno-
suppression. Functional responsiveness of mature NK cells 
can be reconfigured when they encounter an altered MHC 
environment [102], suggesting that donor NK cells can be 
“re-educated” by host HLA. These “re-educated” donor NK 
cells can acquire cytotoxicity against host tumor cells with-
out causing GvHD. Quite a few cases using allogeneic 
T-cell-depleted hematopoietic cell transplantation from 
haploidentical donors in patients with AML have showed 
that NK cells can effectively control AML relapse and im-
prove engraftment without causing GvHD [103–105], sup-
porting that mature haploidentical NK cells alone may pro-
vide a pivotal role in achieving anti-tumor responses. Based 
on these important findings, a series of clinical trials 
showed convincing evidence that allogeneic NK cells dis-
play great therapeutic efficacy in controlling human malig-
nancies. Koehl et al. [106] developed a protocol for clini-
cal-use of highly enriched and IL-2-stimulated NK cells and 
infused these haploidentical NK cells to 3 pediatric leuke-
mia patients. No GvHD response was observed and NK cell 
therapy was well tolerated. The similar efficacy was ob-
served in trials by Passweg who infused haploidentical NK 
cells into 5 leukemia candidates after haploidentical hema-
topoietic stem cell transplantation (HSCT) [107]. Miller and 
his colleague performed a series of clinical trials using 
adoptively transferred haploidentical allogeneic NK cells to 
treat AML patients, including pediatric AML patients and 
older AML patients. They first reported that 5 out of  
19 poor prognosis AML patients achieved complete  
remission [108]. They further reported that ten pediatric 
patients have a disease free survival rate of 100% at a me-
dian of 2 years follow-up after infused mismatched NK 
cells and high doses of IL-2 [109]. In addition, a clinical 
trial of older AML patients reported that 3 of 6 patients in 
CR remained disease-free at 34, 32, and 18 mon, respec-
tively [110]. Besides hematopoietic-derived tumors, strate-
gies using adoptively transferred human-mismatched (hap-
loidentical) allogeneic NK cells also provide effectiveness 
on solid cancers, including HCC, NSCLC, colorectal cancer 
ovarian and breast cancer [21,108,111,112]. 
2.4  Applications of chimeric antigen receptor (CAR)- 
expressing NK cells 
Chimeric antigen receptors (CARs) are engineered receptors 
that consist of an external antibody-derived targeting do-
main fused with one or more intracellular signaling do-
mains. The external domain is responsible for targeting an-
tigens either overexpressed or expressed uniquely on the 
surface of tumor cells, whereas the intracellular domain is 
designed to transmit the activating signal. When expressed 
by lymphocytes, CARs are able to enhance specific target-
ing and activation towards various malignancies. Based on 
the revolutionary effect of CAR-T cell therapy in cases of 
ALL and CLL, cell-based therapies are becoming increas-
ingly promising for the treatment of cancer. The develop-
ment of CAR-T cell-based therapies is accelerating the 
clinical emergence of tumor immunotherapy, but T cell- 
related transplantations must be restricted to autologous 
cells because T cells are major cause of graft-versus-host- 
disease (GvHD). In contrast, NK cells are not responsible 
for GvHD as they do not require HLA matching, and can be 
used as allogeneic effector cells [113], which makes 
NK-based therapies a viable alternative for adoptive immu-
notherapy. Transplanted allogeneic donor NK cells mediate 
reduction of GvHD by inhibiting activated, alloreactive T 
cells while retaining graft-versus-tumor (GvT) effects [110]. 
It has also been reported that the expression of CARs in NK 
cells may allow these cells to more effectively kill solid 
tumors that are often resistant to NK cell-mediated cytotox-
icity [108,112]. As such, CAR-expressing NK cells have 
therefore gained clinical significance providing a targeted 
and allogeneic cell population that universally treats refrac-
tory malignancies. 
To date, numerous pre-clinical investigations have used 
CAR-modified peripheral blood NK cells (PBNK) or 
NK-92 cells to direct against HER-2, CD244, CD19, CD20 
and so on (reviewed in ref. [3,114]). Moreover, authorities 
have approved two clinical studies using CAR-expressing 
NK cells for the treatment of B-lineage ALL. One of the 
clinical studies (NCT00995137) is aimed to identify the 
maximum tolerance dose of genetically modified NK cells 
for patients with relapsed or refractory B-lineage ALL at St. 
Jude Children’s Research Hospital. In this clinical study, 
allogeneic NK cells were first expanded by co-culture with 
irradiated K562 cells that were modified to express mem-
brane bound IL-15 and 41BB ligand (K562-mb15-41BBL)- 
overexpression of these proteins promotes selective growth 
of NK cells. The in vitro expanded NK cells were then 
transduced with vectors encoding a signaling receptor that 
binds to CD19 which is only expressed on B-lineage ALL 
cells. A similar study (NCT01974479) performed by the 
National University Hospital in Singapore investigated the 
persistence and phenotype of redirected NK cells in partici-
pants with residual B-lineage ALL after chemotherapy. In 
that study, donor NK cells were activated and expanded by 
K562-mb15-41BBL cell line combined with IL-2 and then 
transduced with vectors encoding a signaling receptor tar-
geting CD19. 
Although extensive pre-clinical studies have led to suc-
cessful clinical phase I/II studies with CAR-T cells, differ-
ent safety concerns persist for such long-lived high-
ly-proliferative effector cells. These concerns include 
on-target/off-tumor effects, induction of GvHD, tumor lysis 
syndrome and cytotoxicity to normal tissues due to selectiv-
ity restrictions of the chosen target antigen [115–117]. To 
eliminate such side effect, various “suicide systems” have 
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been developed to improve the safety of cell therapy [118] 
by limiting the amount of time that CAR-engineered effec-
tor cells circulate in patients. To date, no such systems have 
been introduced for mature allogeneic CAR-engineered NK 
cells, as they are expected to induce anti-tumor effects and 
disappear after a few days [111]. Theoretically, however, 
such systems may be required in some NK cell-based thera-
pies, as different subsets, such as umbilical cord NK cells, 
and immature NK cells can circulate for weeks to months, 
and as a result, may exhibit notable side effects if used in 
chimera-based therapies. The absolute necessity of a suicide 
switch in CAR-NK cell therapy still requires further inves-
tigation. 
2.5  Adoptive transfer of memory-like NK cells 
Immunological memory is a phenomenon that describes the 
elicitation of more robust reactions by immune cells to cer-
tain antigens that have been previously recognized. These 
cells, called memory cells, are phenotypically and epigenet-
ically distinct from their naive counterparts and can be 
maintained in the human body for a few months, or even 
decades, to provide protection from the secondary invasion 
of the same pathogen. NK cells, which are classified as in-
nate immune cells, have been considered incapable of un-
dergoing somatic rearrangements to confer antigen specific-
ity and forming memory. In contrast to this long-held para-
digm, a subset of NK cells have recently been shown to be 
long-lived and mediate adaptive or ‘‘memory-like’’ re-
sponses to certain antigens in both mice and human, in-
cluding viruses and haptens [119–122]. This subset of 
memory cells exhibits enhanced expansion and effector 
function following a secondary antigen challenge. Many 
people have been infected with HCMV (50%–100% de-
pending on geographical location), and remain infected for 
life (9). Interestingly, many groups have reported that 
HCMV reactivation after allogeneic hematopoietic cell 
transplantation (allo-HCT) imposes a long lasting effect on 
relapses in patients with AML. Using multivariate analysis 
of time-dependent covariate functions for grades II to IV 
acute and chronic GvHD, Elmaagacli et al. [123] first con-
firmed that the reduced relapse risk is involved with early 
HCMV reactivation. Further analysis of a large cohort of 
patients receiving allo-HCT has identified that HCMV reac-
tivation is associated with a reduced risk of early relapse in 
patients with AML but not in patients with ALL, MDS, 
lymphoma and chronic myeloid leukemia (CML) [124]. 
Recently, Shivaprasad et al. [125] has reported that the im-
pact of HCMV reactivation on relapse after allo-HCT in 
AML patients is influenced by conditioning regimens. 
HCMV reactivation can significantly reduce the risk of re-
lapse in patients who received myeloablative (MA) cohort 
but not in those with reduced intensity conditioning (RIC) 
regimens. HCMV reactivation probably induces expansion 
of NKG2C+ memory-like NK cells, as described above 
(section 2.3). However, it remains unknown whether this 
subset of “memory-like” NK cells directly contributes to the 
reduced relapse in patients with AML. A better understand-
ing of “memory-like” NK cell biology would be important 
for further clinical utility. 
Besides HCMV-Induced “memory-like” NK cells, 
Yokoyama and colleagues have found that activation of NK 
cells overnight in vitro with IL-12, IL-18, and IL-15 also 
leads to generation of NK cells with memory-like properties 
in mice [126] as well as in human [127]. Based on a series 
of basic investigations and preclinical studies [126–131], a 
phase I trial (NCT01898793) at Washington University 
School of Medicine was conducted to study the side effects 
and best dose of activated NK cells in treating patients with 
relapses or refractory AML and MDS. In this study, patients 
first received chemotherapy to inhibit cancer cell growth 
before infused with cytokine-induced memory-like (CIML) 
NK cells to induce anti-tumor responses. 
 
 
Figure 3 (color online)  Future perspectives to optimize NK cell-based immunotherapy. 
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3  Outlook 
Current efforts in immunotherapy have focused mainly on 
boosting T-cell responses to tumors. More effective ap-
proaches depend on mobilization of effector cells that be-
long to both the adaptive (T-cell) as well as the innate im-
mune system to induce cooperative antitumor activity. The 
clinical studies reviewed the above provided ample evi-
dence that NK cell-based cancer immunotherapy is both 
feasible and promising. However, there remain many ques-
tions and challenges in this field (Figure 3). For example, 
the out- comes of NK cell immunotherapy are still unpre-
dictable, especially in solid tumors. Moreover, an improved 
study in the role of different subsets, receptor acquisition, 
memory- like responses and in vitro/in vivo expansion ki-
netics of NK cells will be pivotal for designing strategies to 
enhance the clinical efficacy. Despite the questions that are 
yet unanswered, it is reasonable to believe that NK 
cell-based immunotherapy may revolutionize the prospects 
for cancer therapy. 
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